SPIRARE II Results Published for Jupiter’s Vertex Thrombectomy System

October 20, 2026—Jupiter Endovascular, Inc. announced that the full results of the SPIRARE II pivotal trial, evaluating the company’s Vertex thrombectomy system in patients with acute, intermediate-risk pulmonary embolism (PE), were published in EuroIntervention by Sameh Sayfo, MD, et al.

Penumbra’s CAVT Technology Cleared for DVT Indication

October 20, 2026—Penumbra, Inc. announced that the FDA has granted clearance for the treatment of deep vein thrombosis (DVT) to the company’s Lightning computer-assisted vacuum thrombectomy (CAVT) technology.

FDA Approves Haemonetics PerQseal Elite Vascular Closure System

October 20, 2026—Haemonetics Corporation announced FDA approval of the PerQseal Elite vascular closure system for large-bore arterial procedures.

Subgroup Analysis From PERFORMANCE II Presented for Neuroguard IEP Carotid Stent System

October 16, 2026—At VIVA 2026, the Vascular InterVentional Advances conference, William A. Gray, MD, presented findings from a subgroup analysis of the PERFORMANCE II pivotal trial for the Neuroguard integrated embolic protection (IEP) 3-in-1 carotid stent system (Contego Medical LLC, distributed in the United States by Medtronic), which uses dual filtration and a purpose-built carotid stent&; In March 2026, Dr. Gray presented the 3-year outcomes from the trial at ISET.

BD’s Rotarex to Treat CLTI Evaluated in Interim Findings from XTRACT Registry 

October 16, 2026—Interim findings from the prospective, international XTRACT registry for the Rotarex rotational excisional atherectomy system (Becton, Dickinson and Company [BD]) in patients with chronic limb-threatening ischemia (CLTI) were presented by Prakash Krishnan, MD, at VIVA 2026, the Vascular Interventional Advances conference.

ELEGANCE Registry Reports 12-Month Eluvia DES Outcomes in Complex PAD

October 16, 2026—The ELEGANCE registry, which focuses on historically underrepresented populations to generate real-world evidence, evaluated endovascular treatment of peripheral artery disease (PAD) with the Ranger drug-coated balloon or Eluvia drug-eluting stent (DES; both Boston Scientific Corporation).

PROMISE III Reports 1-Year Outcomes With TADV Using the LimFlow System

October 16, 2026—One-year results from the prospective, multicenter, single-arm PROMISE III trial evaluated transcatheter arterialization of the deep veins (TADV) with the LimFlow system (Stryker Peripheral Vascular) in patients with chronic limb-threatening ischemia (CLTI).

Esprit BTK Postapproval Study Reports 6-Month Outcomes

October 16, 2026—Six-month results from Esprit BTK PAS were reported in patients with chronic limb-threatening ischemia (CLTI) treated with the Esprit below-the-knee (BTK) drug-eluting resorbable scaffold (DRS; Abbott).

HI-PEITHO Analysis Studies Predictors of Major Bleeding in Acute Intermediate-Risk PE

October 16, 2026—A post hoc analysis of the randomized HI-PEITHO study examined potential predictors of major bleeding in patients with acute intermediate-risk pulmonary embolism (PE) treated with ultrasound-facilitated catheter-directed thrombolysis (USCDT) using the Ekos endovascular system (Boston Scientific Corporation) plus anticoagulation (AC) or anticoagulation (AC) alone.

POWER PAD II Study of Pulse IVL System Meets Endpoints

October 16, 2026—Results from the prospective, single-arm, multicenter POWER PAD II study demonstrated that the Pulse intravascular lithotripsy (IVL) system (Amplitude Vascular Systems, Inc., recently acquired by Stryker) met its primary safety and effectiveness endpoints in patients with calcified femoropopliteal artery disease.